Efficacy of FPF 1070 (cerebrolysin) in patients with Alzheimer's disease. A multicentre, randomised, double-blind, placebo-controlled trial

Clinical Drug Investigation

Volumn 19, Issue 1, 2000, Pages 43-53

  Shifu, Xiao ^a   Heqin, Yan ^a   Peifen, Yao ^a   Luning, Wang ^b   Jianjun, Jia ^b   Xin, Ma ^c   Feng, Bao ^c   Jie, Long ^d   Chunxie, Wang ^d   Zhihua, Dai ^h   Mingyi, Zhang ^h   Wenzhen, Xu ^e   Yinglu, Gou ^e   Cui, Ma ^f   Daping, Wang ^f   Binhua, Su ^g  

^a SHANGHAI MENTAL HEALTH CENTER   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Beijing An Ding Hospital   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e WEST CHINA UNIVERSITY OF MEDICAL SCIENCES   (China)

^f Guangzhou Psychiatric Hospital   (China)

^g SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEREBROLYSIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; TREMOR; VERTIGO;

EID: 0033968278     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019010-00006     Document Type: Article

References (28)

1. Zhang MY, Katzman R, Jin H, et al. The prevalence of dementia and Alzheimer disease in Shanghai, China. Ann Neurol 1990; 27: 428-37
2. Katzman R, Saitoh T. Advances in Alzheimer disease. FASEB J 1991; 5: 278-86
3. Molloy DW, Gordon H, Guyatt DB. et al. Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease. Can Med Assoc J 1991; 144: 129-34
4. American Psychiatric Association. Practice guideline for the treatment of patients with Alzheimer disease and other dementias of late life. Am J Psychiatry 1997; 5 Suppl.: 1-39
5. Windisch M, Albrecht U, Eggenreich B. Neurotophic effects of cerebrolysin. Neurobiol Aging 1992; 13 Suppl.: 133-8
6. Piswanger A, Paier B, Windisch M. Modulation of protein synthesis in a cell-free system from rat brain by cerebrolysin during development and aging. Amino Acids 1990; 3: 651-7
7. Baskys A, Wojtowicz JN. Actions of organ derived preparations on synaptic transmission in the hippocampus. Neurobiol Aging 1992; 13 Suppl.: 128-32
8. Kofler B, Erhart C, Erhart P, et al. About the therapeutic efficacy of cerebrolysin. Psychology 1989; 8: 29-33
9. Akai F, Hiruma S, Sato T. et al. Neurotrophic factor-like effect of 1070 on septal cholinergic neurones after transections of fimbria-fornix in the rat brain. Histol Histopathol 1992; 7: 213-21
10. Trojanova M. Influence of cerebrolysin on the resistance of rats to anoxia. Physiol Bohemoslov 1975; 25: 319-23
11. Windisch M, Piswanger A. Changes of brain metablism of rats due to long term treatment with a peptide derivative. Drug Res 1985; 35: 1353-6
12. Albrecht E, Hingel S. The effects of cerebrolysin on the vitality and sprouting of neurons from cerebral hemispheres and from the brain stem of chicken embryos in vitro. Neurobiol Aging 1992; 13 Suppl.: 127-31
13. Kofler B, Erhart C, Erhart P. et al. A multidimensional approach in testing nootripic drug effects (cerebrolysin). Arch Gerontol Geriatr 1990; 10: 129-40
14. Ruther E, Ritter R, Apeccechea M, et al. Efficacy of the peptidergic nootropgie drug cerebrolysin in patients with senile dementia of Alzheimer type. Pharmacopsychiatry 1994; 27: 32-40
15. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed rev. Washington, DC. American Psychiatric Association 1987
16. McKhann G, Drachman D, Folstein M, et al. Report of the NINCDS-ADRDA work group under the auspices of the department of Health and Human Services Task Force on Alzheimer Disease. Neurology 1984; 34: 939-44
17. Folstein MF, Folstein SE, Huge BK, et al. Mini Mental State Examination: a practical method for grating the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 1989-98
18. Hachinski VC, Iliff I.D, Zilhka E, et al. Cerebral blood flood flow in dementia. Arch Neurol 1975; 32: 632-7
19. Reisherg B, Ferris SH, De Leon MJ, et al. An instrument for the assessment of primary degenerative dementia (PDD). Am J Psychiatry 1982; 139: 1136-9
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62
21. National Institute of Mental Health: Clinical Global Impression. In: CIPS-Collegium Internationale Psychiatriae Scalarum, editors. Internationale Skalen fur Psychiatrie. Beltz Test, 1986
22. Oswald WD. Der Zahlen-Verbindungs-Test im hoheren leben-salter. In: Aspekte Psychologischer Forschung. Hogrefe, Gottingen: 1986; 377-88
23. Shader R, Harmatz JS, Salzman C. A new scale for clinical assessment on geriatric populations: Sandoz Clinical Assessment-Geriatric (SCAG). J Am Geriatr Soc 1974; 22 (3): 107-13
24. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in aged: the index of ADL, a standardized measure of biological and psychosocial funtion. JAMA 1963; 185: 94-106
25. Oswald WD, Fleischmann UM. Nurnherger-Alters-Inventar NA1. Testkasten und Manual. Hogrefe, Gottingen: 1992
26. Hebenstreit GF. Die Wirkung eines aminosature-peptid-extraktes beizerebralen funktionsstorrungen in geronton-psychitrie. Neuropsychiatre 1986; 1: 38-44
27. Vereshchagin N, Lebedeva NV, Suslina ZA, et al. Mild forms of multiinfaret dementia: effectiveness of cerebrolysin. Sowj Med 1991; 11: 6-8
28. Xiong H, Wojtowicz J, Baskys A. Brain tissue hydrolysate acts on presynaptic adenosine receptors in the rat hippocampus. Can J Physiol Pharmacol 1995; 73: 1194-7